# The overnight test of weight loss therapies

> Weight loss therapies meet the sleeping body: tirzepatide, obstructive sleep apnea, oxygen burden and the day after, examined through published trials.

**Sleep, weight and waking life**

A falling weight leaves a whole night unaccounted for. I’m interested in breathing during sleep—and whether a better recording comes with an easier day.

## Tirzepatide in the sleep laboratory

In [SURMOUNT-OSA, tirzepatide reduced breathing events during sleep more than placebo](https://pubmed.ncbi.nlm.nih.gov/38912654/) in adults with obesity and moderate-to-severe obstructive sleep apnea. The trials lasted 52 weeks and included separate groups with and without PAP use. Their central measurement was the apnea-hypopnea index, or AHI: breathing events counted per hour of sleep.

I came to “weight loss therapies” thinking about scales. The sleep trial rewarded a different curiosity. A therapy associated with weight loss was being tested against a problem that had its own overnight record. That seems a much more interesting use of the word “therapies” than a competition over the largest percentage.

> The sleeping body supplies a test of its own.

## Breathing events, oxygen and waking life

The first sleep paper opens several doors. A later [analysis of timing and oxygen burden](https://pubmed.ncbi.nlm.nih.gov/41135142/) connected the size of the sleep changes with achieved weight reduction. Another report examined [sleep and quality of life as participants described them](https://pubmed.ncbi.nlm.nih.gov/40774158/).

That double account of the night suits my curiosity. An instrument records something the sleeper may never notice. A questionnaire asks about the experience of living through the night and the following day. Both deserve space; their agreement would interest me, and so would a disagreement.

- [The sleep trials](/sleep-apnea) put the breathing-event results beside the PAP groups.
- [Oxygen and time](/oxygen-and-time) examines why the early signal and the placebo comparison have different dates.
- [The daytime account](/daytime) considers the participants’ answers about sleep, impairment and daily activity.

## Treatment brings its own burdens

There is a less restful side to this subject. In a separate [obesity trial, gastrointestinal adverse effects were the most common adverse events](https://pubmed.ncbi.nlm.nih.gov/35658024/), mostly mild to moderate and occurring primarily during dose escalation. Those findings come from the weight-management setting; they do not measure how a particular person’s sleep will change.

I distrust relief described with the treatment’s discomforts quietly left outside the frame. The [treatment trade-offs](/treatment-tradeoffs) deserve a page beside the sleep findings. The [reading list](/references) brings together the trial reports and the safety work used here.

---

At Weight Loss Therapies my curiosity follows published research into the sleeping hours; this is an editorial site, not a treatment business, and these pages offer no medical advice.